P. Comella

发表

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.

V. Lorusso, G. Comella, N. Panza, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells

P. Delrio, M. Caraglia, F. Bruzzese, 2007, Anti-cancer drugs.

Locally Advanced Rectal Cancer: Combined Chemotherapy During Preoperative Radiation Therapy

P. Delrio, A. Avallone, A. Budillon, 2009 .

Chemo-radiotherapy in locally advanced rectal cancer: What is the optimal strategy?

P. Delrio, A. Avallone, S. Lastoria, 2008 .

Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.

G. Botti, C. Pacilio, G. Comella, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Colorectal Cancer: Focus on Capecitabine

P. Delrio, A. Avallone, B. Pecori, 2010 .

Role of oxaliplatin in the treatment of colorectal cancer

A. Avallone, C. Sandomenico, P. Comella, 2009, Therapeutics and clinical risk management.

Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet

A. Avallone, C. Sandomenico, P. Comella, 2010, Acta oncologica.

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

E. Van Cutsem, A. Santoro, J. Douillard, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase II trial.

A. Gambardella, A. Avallone, B. Massidda, 2007, Lung cancer.

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group.

F. D. De Braud, R. Franchi, F. Bozzetti, 1994, European journal of cancer.

Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study.

F. Fiore, G. Comella, A. Daponte, 1997, Seminars in oncology.

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

C. Pacilio, T. Guida, G. Comella, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.

R. Thomas, G. Botti, G. D'aiuto, 2001, Seminars in oncology.

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5‐fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck

F. Caponigro, A. Avallone, G. Comella, 1999 .

Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy

F. Caponigro, A. Avallone, A. Budillon, 2001, Anti-cancer drugs.

Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.

H. McLeod, F. Caponigro, A. Avallone, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).

F. Caponigro, E. Di Gennaro, A. Avallone, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).

F. Selvaggi, V. Lorusso, M. de Lena, 1996, Journal of chemotherapy.

Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.

P. Comella, 2001, Seminars in oncology.

Cisplatin, Raltitrexed, Levofolinic Acid and 5-Fluorouracil in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study

F. Caponigro, A. Avallone, G. Comella, 2002, Oncology.

Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.

F. Fiore, G. Comella, A. Daponte, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I–II Study on a Gemcitabine-Cyclophosphamide-Fluorouracil/Folinic Acid Triplet Combination in Anthracycline- and Taxane-Refractory Breast Cancer Patients

P. Vallone, G. D'aiuto, G. Botti, 2002, Oncology.

Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III tria.

R. Thomas, A. Russo, A. Petrillo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial.

R. Thomas, A. Russo, G. Comella, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study.

R. Thomas, M. Rinaldo, M. di Bonito, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).

R. Thomas, P. Vallone, G. Botti, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A risk model for ovarian carcinoma patients using CA 125: Time to normalization renders second‐look laparotomy redundant

F. Zullo, G. Comella, G. Persico, 1996, Cancer.

Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.

P. Muto, S. Quattrin, S. Tafuto, 2006, Frontiers in bioscience : a journal and virtual library.

Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma

A. Gambardella, V. Lorusso, S. Tafuto, 2005, Cancer.

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401

G. Filippelli, B. Massidda, P. Comella, 2009, Journal of Cancer Research and Clinical Oncology.

Prognostic relevance of urinary neopterin in non‐Hodgkin's lymphomas

P. Comella, G. Santelli, F. Nitsch, 1989, Cancer.

Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

A. Abbruzzese, M. Caraglia, F. Caponigro, 2003, Journal of cellular physiology.

A review of the role of capecitabine in the treatment of colorectal cancer

P. Comella, 2007, Therapeutics and clinical risk management.

Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma.

F. Izzo, G. Botti, F. Galimi, 2011, Oncology reports.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study

G. D'aiuto, F. Caponigro, A. Budillon, 1998, Breast Cancer Research and Treatment.

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).

A. Gambardella, M. Ghiani, M. Roselli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.

A. Bianco, G. Comella, N. Panza, 1996, British Journal of Cancer.

Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial.

E. Biondi, G. Comella, N. Panza, 1996, Lung cancer.

Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.

G. D'aiuto, L. Vizioli, M. Santangelo, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin-Oral Etoposide Personalised Dosing in Elderly Non-small Cell Lung Cancer Patients

P. Marcatili, S. Monfardini, G. Comella, 1998 .

Phase I/II study of carboplatin and oral etoposide with granulocyte‐colony stimulating factor in advanced nonsmall cell lung cancer

G. Comella, M. Polverino, G. Persico, 1995, Cancer.

Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine vs. either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small-cell lung cancer. A Southern Italy Cooperative Oncology Group Study.

V. Lorusso, G. Comella, N. Panza, 2000, Clinical lung cancer.

Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.

F. Carpagnano, V. Lorusso, M. de Lena, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.

F. Carpagnano, C. Pacilio, V. Lorusso, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials.

A. Gambardella, A. Avallone, R. Costanzo, 2008, Critical reviews in oncology/hematology.

Efficacy and tolerability of oxaliplatin plus fluoropyrimidines in elderly patients with metastatic colorectal carcinoma: the SICOG experience

P. Comella, 2006 .

Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.

V. Lorusso, M. Roselli, G. Filippelli, 2005, Clinical colorectal cancer.

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.

V. Lorusso, M. Roselli, G. Filippelli, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

M. Guida, N. Panza, G. Filippelli, 2004, British Journal of Cancer.

Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study

G. Comella, F. Salzano, G. Persico, 1995, Breast Cancer Research and Treatment.

Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement.

G. Comella, G. Galizia, F. Salzano, 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).

Optimizing the management of metastatic colorectal cancer.

A. Avallone, P. Comella, R. Casaretti, 2010, Critical reviews in oncology/hematology.

Cisplatin–epirubicin–paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology group (SICOG) phase II study

G. D'aiuto, I. Capasso, M. Bonito, 2000, Breast Cancer Research and Treatment.

Cisplatin–epirubicin–paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group

G. D'aiuto, I. Capasso, M. Bonito, 1999, Breast Cancer Research and Treatment.

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

M. Rinaldo, G. D'aiuto, A. Petrillo, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies.

V. Lorusso, G. Comella, G. Catalano, 1996, European journal of cancer.

Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma

P. Ascierto, G. Palmieri, R. Cellerino, 2000 .

Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.

G. Comella, A. Gallipoli, A. Daponte, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.

V. Lorusso, M. de Lena, M. Lena, 2005, Oncology Report.

Combination Chemotherapy (CVP or Chop)-Radiotherapy Approach in Early Stage Non-Hodgkin's Lymphomas

G. Castello, G. Comella, G. Apice, 1982, Tumori.

Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).

F. Caponigro, A. Avallone, G. Mantovani, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of resistant non-Hodgkin’s lymphomas with cisplatin, etoposide, and bleomycin

A. Daponte, P. Comella, G. Abate, 2008, Cancer Chemotherapy and Pharmacology.

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

A. Russo, G. Comella, N. Panza, 2001, British Journal of Cancer.

Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I–II study

P. Delrio, A. Avallone, A. Budillon, 2006, British Journal of Cancer.

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study

P. Vallone, G. D'aiuto, G. Botti, 2007, Cancer Chemotherapy and Pharmacology.

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study

P. Vallone, G. D'aiuto, G. Botti, 2003, Cancer Chemotherapy and Pharmacology.

A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study

R. Thomas, G. D'aiuto, M. Bonito, 2005 .

Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial

Antonella Petrillo, Vincenza Granata, Gerardo Botti, 2015, Oncotarget.

Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.

F. Izzo, F. Fiore, A. Avallone, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.

A. Avallone, V. Lorusso, M. de Lena, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.

P. Delrio, A. Avallone, A. Budillon, 2011, International journal of radiation oncology, biology, physics.

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.

F. Caponigro, J. Bryce, A. Avallone, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of vinorelbine, cisplatin, and etoposide in advanced non-small cell lung carcinoma: a pilot study.

G. Palmieri, G. Comella, A. Daponte, 1994, Journal of chemotherapy.

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study

R. Thomas, G. Botti, G. D'aiuto, 2006, British Journal of Cancer.

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

V. Lorusso, M. de Lena, G. Comella, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biweekly Docetaxel-Irinotecan Treatment with Filgrastim Support Is Highly Active in Antracycline-Paclitaxel-Refractory Breast Cancer Patients

P. Vallone, G. D'aiuto, G. Botti, 2005, Oncology.

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Prognosis in Extensive Disease Small-Cell Lung Cancer

A. Russo, G. Comella, I. Carreca, 2005, Oncology.

Urinary Neopterin Levels in Hematologic Malignancies

P. Comella, F. Nitsch, G. Abate, 1986, Tumori.

Gemcitabine P lus V inorelbine V ersus V inorelbine A lone i n Elderly P atients W ith A dvanced N on-Small-Cell Lung C ancer

V. Lorusso, M. Lena, G. Comella, 2000 .

Changes in FDG uptake during preoperative radiochemotherapy predict prognosis in patients with locally advanced rectal cancer (LARC)

P. Delrio, A. Avallone, G. Cascini, 2007 .

Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.

S. Tafuto, F. De Vita, F. Del Gaizo, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.

A. Avallone, G. Comella, G. Catalano, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial.

V. Lorusso, M. de Lena, G. Comella, 2001, Lung cancer.

Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial

V. Tinessa, G. Ianniello, A. Lombardi, 1996, Cancer.

Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia.

P. Marcatili, S. Monfardini, G. Comella, 1998, European Journal of Cancer.

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients

A. Avallone, V. Lorusso, G. Comella, 2002, British Journal of Cancer.

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study

S. Tafuto, B. Massidda, P. Comella, 2005, Cancer Chemotherapy and Pharmacology.

A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.

A. Gambardella, V. Lorusso, S. Tafuto, 2005, Critical reviews in oncology/hematology.

Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma

A. Gambardella, V. Lorusso, P. Comella, 2003, British Journal of Cancer.

18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

Cesare Guida, Giuseppe Lucio Cascini, Antonio Avallone, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.

P. Comella, 2003, Clinical colorectal cancer.

Capecitabine, Alone and in Combination, in the Management of Patients with Colorectal Cancer

A. Avallone, C. Sandomenico, P. Comella, 2012, Drugs.

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.

A. Avallone, G. Filippelli, R. Costanzo, 2010, Lung cancer.

18 F-FDG PET Is an Early Predictor of Pathologic Tumor Response to Preoperative Radiochemotherapy in Locally Advanced Rectal Cancer

P. Delrio, A. Avallone, F. Tatangelo, 2006 .

Irinotecan and Mitomycin C in 5-Fluorouracil-Refractory Colorectal Cancer Patients

A. Avallone, G. Comella, M. Biglietto, 2001, Oncology.

Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.

G. Castello, M. Napolitano, G. Comella, 1993, Melanoma research.

Enhancement of C.E.V combination (cisplatin, epirubicin, vindesine) in advanced NSCLC by lonidamine. A phase II randomized trial

G. Ianniello, P. Comella, L. Brancaccio, 1994 .

Real-time contrast-enhanced specific ultrasound in staging and follow-up of splenic lymphomas.

O. Catalano, G. Barba, S. Quattrin, 2006, Frontiers in bioscience : a journal and virtual library.

A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.

R. Thomas, G. Botti, G. D'aiuto, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly cisplatin-paclitaxel-topotecan (CPT) as front-line therapy for extensive disease small cell lung cancer (ED-SCLC). A Southern Italy Cooperative Oncology Group (SICOG) phase II study

A. Russo, G. Comella, N. Panza, 2000 .

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer

F. Izzo, F. Fiore, C. Sandomenico, 2006, Anti-cancer drugs.

Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.

C. Sandomenico, G. Filippelli, S. Tafuto, 2011, Clinical colorectal cancer.

Evolution of combined modality therapy for stage III non-small-cell lung cancer.

P. Comella, 2000 .

Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.

A. Avallone, G. Catalano, G. Comella, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.

P. Delrio, A. Avallone, A. Budillon, 2011, International journal of radiation oncology, biology, physics.

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.

P. Ascierto, G. Palmieri, R. Cellerino, 2000, Cancer.

Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.

F. Fiore, F. Caponigro, F. Ionna, 1997, European journal of cancer.

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group

V. Lorusso, M. Roselli, C. Sandomenico, 2009, Cancer Chemotherapy and Pharmacology.

Oxaliplatin (OXA) plus folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus (OXAFAFU) versus irinotecan (IRI) plus FA and FU i.v. bolus (IRIFAFU) in advanced colorectal carcinoma (ACC): Activity and toxicity results of the SICOG 0103 randomized trial.

G. Filippelli, S. Tafuto, F. De Vita, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New drugs in non-small cell lung cancer.

P. Comella, 2000, Tumori.

Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

V. Lorusso, M. Lena, G. Comella, 2000 .